ASH 2021 – Paolo Ghia
Paolo Ghia highlights what modern targeted agents can achieve in terms of undetectable minimal residual disease in the management of patients with CLL and important methodological recommendations to ensure correct assessment of TP53 and IGHV mutational status. He explains how the three epigenetic subgroups (m-CLL, n-CLL, i-CLL) are related, what effect a thorough immunogenetic analysis has on the risk stratification of patients with CLL and gives an overview about the most interesting findings on the management of pretreated CLL patients.
Here is the full ASH 2021 report.
More posts
Preface
The 63rd Annual Meeting of the American Society of Hematology (ASH) took place as a hybrid event that hosted participants both online and on-site in Atlanta, Georgia, USA. Among the multitude of updates and new insights presented from December 11 to 14, 2021, results obtained for targeted therapies in B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenström’s macroglobulinemia, and marginal zone lymphoma are summarized in this issue of memo inHaematology.